Abstract:

Objective　To explore the therapeutic effect of Tongxinluo combined with Shensong Yangxin capsules on patients with ventricular arrhythmia. Methods　It was a randomized controlled trial. A total of 138 patients with ventricular arrhythmia admitted to Puyang Huimin Hospital from January 2021 to January 2022 were selected and were divided into a control group and an observation group by the random number table method with 69 patients in each group. The control group included 37 males and 32 females, aged (61.48±9.42) years; the observation group included 34 males and 35 females, aged (61.52±9.67) years. The patients in the control group were treated with conventional western medicine, and the patients in the observation group were treated with Tongxinluo and Shensong Yangxin capsules on the basis of the control group. The curative effects, heart function, electrocardiographic indicators, and adverse reactions were compared between the two groups. t test and χ² test were used. Results　The total effective rate of the observation group was 94.20% (65/69), which was higher than that of the control group [69.57% (48/69)], with a statistically significant difference (χ²=14.118, P<0.001). After one month of treatment, the left ventricular ejection fraction (LVEF) in the observation group [(58.98±2.69)%] was higher than that in the control group [(53.58±2.88)%], while the left ventricular end-diastolic diameter (LVEDD) [(51.69±3.47) mm] and left ventricular end-systolic volume (LVESV) [(77.92±11.43) mm] were lower than those of control group [(56.75±3.61) mm and (86.37±12.79) mm], with statistically significant differences (all P<0.05). After one month of treatment, the atrioventricular conduction time (PR interval) in the observation group [(201.28±25.25) ms] was higher than that in the control group [(186.61±20.39) ms], while the time of ventricular depolarization to complete repolarization (QT interval) [(347.11±13.29) ms] and QT dispersion (maximum QT interval - minimum QT interval) [(41.17±9.63) ms] were lower than those in the control group [(363.35±15.58) ms and (52.96±10.13) ms], with statistically significant differences (all P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the observation group and the control group [5.80% (4/69) vs. 4.35% (3/69)] (χ²=0.151, P=0.698). Conclusion　Tongxinluo combined with Shensong Yangxin capsules can achieve the good results in the treatment of patients with ventricular arrhythmia, which can significantly improve their cardiac function and electrical activity, and is safe and reliable, worthy of promotion.

Key words:

Ventricular arrhythmia, Tongxinluo capsules, Shensong Yangxin capsules, Curative effect

摘要：

目的　探析室性心律失常患者采用通心络与参松养心胶囊联合常规西药治疗的效果。方法　本研究为随机对照试验。选择2021年1月至2022年1月濮阳惠民医院收治的室性心律失常患者138例，采用随机数字表法将患者分为对照组与观察组，各69例。对照组男37例、女32例，年龄（61.48±9.42）岁，采用常规西药治疗；观察组男34例、女35例，年龄（61.52±9.67）岁，在对照组基础上加用通心络联合参松养心胶囊治疗。比较两组患者疗效、心功能、心电图指标及不良反应发生率。采用t检验、χ²检验。结果　观察组治疗总有效率为94.20%（65/69），高于对照组69.57%（48/69），差异有统计学意义（χ²=14.118，P<0.001）。治疗1个月后，观察组左心室射血分数（LVEF）［（58.98±2.69）%］高于对照组［（53.58±2.88）%］，左心室舒张末期内径（LVEDD）［（51.69±3.47）mm］、左心室收缩末期容积（LVESV）［（77.92±11.43）mm］均低于对照组［（56.75±3.61）mm、（86.37±12.79）mm］，差异均有统计学意义（均P<0.05）。治疗1个月后，观察组房室传导时间（PR间期）［（201.28±25.25）ms］长于对照组［（186.61±20.39）ms］，心室除极到完全复极时间（QT间期）［（347.11±13.29）ms］短于对照组［（363.35±15.58）ms］，QT间期最大值-QT间期最小值（QT离散度）［（41.17±9.63）ms］低于对照组［（52.96±10.13）ms］，差异均有统计学意义（均P<0.05）。观察组不良反应发生率为5.80%（4/69），与对照组4.35%（3/69）比较，差异无统计学意义（χ²=0.151，P=0.698）。结论　对室性心律失常患者采用通心络与参松养心胶囊联合常规西药治疗可获得良好效果，能改善其心功能及心电活动，安全可靠，值得推广。

关键词:

室性心律失常, 通心络胶囊, 参松养心胶囊, 疗效